Several U.S. Supreme Court justices appeared hesitant Monday to block a $6 billion bankruptcy plan for Purdue Pharma, the maker of OxyContin, that includes controversial legal protections for members of the Sackler family who as the company’s owner allegedly helped fuel the opioid crisis.

The U.S. Trustee Program, a part of the Department of Justice and overseer of the bankruptcy system, has challenged the Chapter 11 plan over its release of liability for the Sacklers in exchange for contributing up to $6 billion to victims of the opioid crisis.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]